Skip to content

Aggressive Fluid Hydration for the Prevention of Post-ERCP Pancreatitis

Aggressive Fluid Hydration for the Prevention of Post-ERCP Pancreatitis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02821546
Enrollment
286
Registered
2016-07-01
Start date
2014-08-31
Completion date
2017-02-28
Last updated
2017-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis

Brief summary

Aggressive hydration with lactated Ringer's solution (LRS) has been shown in a preliminary research to reduce the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. This randomized, controlled trial was designed to assess the effect of peri-procedural aggressive intravenous hydration with LRS on the incidence of post ERCP pancreatitis.

Detailed description

Patients underwent first-time ERCP were randomly assigned (1:1) to receive either LRS at a rate of 150 ml/hr starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours (aggressive hydration) or LRS at a rate calculated by the Holliday-Segar method given peri-procedurally as described earlier (standard hydration). Visual analog scale, serum amylase, lipase, C-reactive protein (CRP), and urine analysis were assessed prior to procedure and 24 hours after. The primary endpoint was post ERCP pancreatitis defined as new or increased epigastric pain persisting for ≥24 hours, elevation of amylase or lipase \>3 times the upper limit of normal.

Interventions

Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid

Sponsors

Mahidol University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* patients at age between 18-65 years old undergoing first time ERCP

Exclusion criteria

* Ongoing acute pancreatitis * Chronic pancreaittis * Prior sphincterotomy * Ongoing hypotension including those with sepsis * Cardiac insufficiency (CI, \>NYHA Class II heart failure) * Renal insufficiency (RI, creatinine clearance \<40mL/min) * Severe liver dysfunction (albumin \< 3mg/dL) * Respiratory insufficiency (defined as oxygen saturation \< 90%) * Pregnancy * Hyponatremia (Na+ levels \< 130mEq/L)) * Hypernatremia (Na+ levels \> 150mEq/L)

Design outcomes

Primary

MeasureTime frameDescription
post ERCP pancreatitis24 hoursPost ERCP pancreatitis is defined as hyperamylasemia (amylase \>3 times the upper limit of normal \[300 U/L\]) and pancreatic pain (epigastric abdominal pain radiating to the back scored by patient as development of or increase of pain ≥3 on a 0-10 visual analogue pain scale and persisting for ≥24 hours after ERCP). In those who had pain before the procedure, pancreatic pain is defined as an increase of ≥3 on the 0-10 visual analogue scale.

Secondary

MeasureTime frameDescription
severity of post ERCP pancreatitis24 hoursseverity is defined by length of hospital stay, mild pancreatitis is defined by hospitalization of 48 hours, moderate pancreatitis is defined by hospitalization of more than 48 hours without additional intervention, severe pancreatitis is defined by hospitalization of greater than 72 hours and/or requiring intervention

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026